Drug development is both a science challenge and timeline challenge. In this episode, Alex Mok shares what it actually takes to build a biotech company in today’s market. From launching an specialized therapeutics platforms to navigating shifting capital markets, Alex breaks down how valuation, risk, and execution intersect in modern drug development.We explore why clinical trial timelines directly shape risk-adjusted NPV, how market cycles influence platform vs. asset strategies, and why operational execution has become the real competitive advantage in biotech.Alex also shares a deeply personal story about trying to enroll his own father in a Phase 1 oncology trial — a firsthand look at how broken clinical operations can delay care and destroy value.The conversation covers timely topics such as AI-native clinical operations, agentic workflows in biotech, capital efficiency in drug development, the impact of automation on enrollment and trial velocity, and what happens when execution risk is materially reduced. If AI meaningfully lowers the cost and friction of clinical development, the biotech landscape changes. More shots on goal, faster proof of concept and different capital dynamics. This episode is for biotech founders, pharma executives, clinical operations leaders, and investors thinking about where the industry goes next.